As described in the morning session, regulatory expectations continue to evolve given the complexities associated with new products and innovation. This session will provide an opportunity to hear more about this topic in the context of an innovative vaccine facility and related sterile manufacturing requirements.
Executive Director, Global Quality & Compliance,
Genentech, A Member of the Roche Group
Executive Director, Supply Chain Management,
Merck & Co., Inc.
Branch Chief, Division of Microbiology Assessment,
Credits: None available.
You must be logged in and own this session in order to